Skip to main content
. 2019 Oct;10(5):957–964. doi: 10.21037/jgo.2019.05.07

Table 2. Chemotherapy regimens and median survival time from the start of each line of chemotherapy.

Variables Total, n=271
First-line regimen, n (%)
   S-1 + cisplatin 144 (53.1)
   S-1 + oxaliplatin 24 (8.9)
   S-1 monotherapy 73 (26.9)
   Trastuzumab containing regimen 7 (2.6)
   Others 23 (8.5)
Second-line regimen, n (%)
   Paclitaxel + ramucirumab 12 (8.1)
   Paclitaxel or docetaxel monotherapy 77 (52.0)
   Irinotecan monotherapy 35 (23.6)
   Others 24 (16.2)
Third-line regimen, n (%)
   Irinotecan monotherapy 35 (49.3)
   Paclitaxel or docetaxel monotherapy 23 (32.4)
   Nivolumab 1 (1.4)
   Others 12 (16.9)
Survival time from the start of the first line, median [IQR], days 234 [133–486]
Survival time from the start of the second line, median [IQR], days 166 [102–323]
Survival time from the start of the third line, median [IQR], days 151 [87–239]

IQR, interquartile range.